105
Participants
Start Date
May 2, 2018
Primary Completion Date
December 31, 2020
Study Completion Date
January 8, 2025
Durvalumab
IV (intravenous)
Tremelimumab
IV
Cisplatin (dose level 4)
IV
Cisplatin (dose level 3)
IV
Carboplatin (dose level 1)
IV
Carboplatin (dose level 2)
IV
Etoposide (dose level 1)
IV
Etoposide (dose level 2)
IV
Paclitaxel
IV
Pemetrexed
IV
External beam radiation (dose level 1)
radiation therapy
External beam radiation (dose level 2)
radiation therapy
External beam radiation (hyperfractionated)
radiation therapy
Cisplatin (dose level 1)
IV
Cisplatin (dose level 2)
IV
External beam radiation (standard)
radiation therapy
Research Site, Taipei
Research Site, Taoyuan
Research Site, Taipei
Research Site, Madrid
Research Site, Málaga
Research Site, Taichung
Research Site, Houston
Research Site, Aurora
Research Site, Tucson
Research Site, Kōtoku
Research Site, Sunto-gun
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Badalona
Lead Sponsor
AstraZeneca
INDUSTRY